Literature DB >> 3038500

Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

D M Campoli-Richards, R N Brogden.   

Abstract

Sulbactam is a semisynthetic beta-lactamase inhibitor which when combined with certain beta-lactam antibacterials extends their activity against bacteria that are normally resistant to the antibiotic due to production of beta-lactamases. In combination with ampicillin it extends the antibacterial activity of ampicillin to include beta-lactamase-producing strains which are otherwise resistant, including Bacteroides fragilis, and increases the susceptibility of many sensitive strains. Sulbactam is poorly absorbed after oral administration and sulbactam/ampicillin is therefore administered parenterally, although another linked sulbactam-ampicillin compound, sultamicillin, has been developed which is well absorbed after oral administration. The basic pharmacokinetic characteristics of sulbactam after parenteral administration are similar to those of ampicillin. Multiple-dose therapy with sulbactam/ampicillin is clinically and bacteriologically effective in infections of the urinary tract, skin and soft tissue, bones and joints, respiratory tract, ears, nose and throat, as well as intra-abdominal and obstetric and gynaecological infections and septicaemia. In addition, single intramuscular doses of sulbactam/ampicillin administered with oral probenecid are therapeutically effective in gonorrhoea, including infections due to penicillinase-producing and/or ampicillin-resistant Neisseria gonorrhoeae. In the prophylaxis of infectious complications of surgery sulbactam/ampicillin is superior to placebo and appears to be similar in efficacy to several alternative antibacterial regimens. Further studies involving larger numbers of patients are needed to clarify the comparative therapeutic and prophylactic efficacy of sulbactam/ampicillin and alternative antibacterial drugs. Nonetheless, sulbactam/ampicillin improves the therapeutic and prophylactic efficacy of an antibacterial of familiar safety, and must be seen as a worthwhile advance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038500     DOI: 10.2165/00003495-198733060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  82 in total

1.  Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn.

Authors:  A M Sutton; T L Turner; F Cockburn; T A McAllister
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

2.  A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections.

Authors:  J F Reinhardt; L Johnston; P Ruane; C C Johnson; L Ingram-drake; K MacDonald; K W Ward; G Mathisen; W L George; S M Finegold
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

3.  Correlation of the effect of beta-lactamase inhibitors on the beta-lactamase in growing cultures of gram-negative bacteria with their effect on the isolated beta-lactamase.

Authors:  C J Easton; J R Knowles
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

4.  6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

5.  In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus.

Authors:  A Kazmierczak; J M Duez; A Pechinot; P Nordmann; R Labia
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

6.  An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections.

Authors:  L Löffler; A Bauernfeind; W Keyl; B Hoffstedt; A Piergies; W Lenz
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients.

Authors:  U B Schaad; K Guenin; P Straehl
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

8.  Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

9.  Cefoxitin, N-formimidoyl thienamycin, clavulanic acid, and penicillanic acid sulfone as suicide inhibitors for different types of beta-lactamases produced by gram-negative bacteria.

Authors:  T Sawai; K Tsukamoto
Journal:  J Antibiot (Tokyo)       Date:  1982-11       Impact factor: 2.649

10.  Characterization of cephalosporinases from Bacteroides fragilis, Bacteroides thetaiotaomicron and Bacteroides vulgatus.

Authors:  K Sato; Y Matsuura; K Miyata; M Inoue; S Mitsuhashi
Journal:  J Antibiot (Tokyo)       Date:  1983-01       Impact factor: 2.649

View more
  22 in total

1.  Influence of substrates and inhibitors on the structure of Klebsiella pneumoniae carbapenemase-2.

Authors:  Ben A Shurina; Richard C Page
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-04

Review 2.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

3.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 4.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

5.  Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  S Mohd Sazlly Lim; A J Heffernan; J A Roberts; F B Sime
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

6.  Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.

Authors:  J Majcher-Peszynska; M Loebermann; S Klammt; S Frimmel; R G Mundkowski; T Welte; E C Reisinger; B Drewelow
Journal:  Infection       Date:  2013-08-01       Impact factor: 3.553

Review 7.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 8.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers.

Authors:  B R Meyers; P Wilkinson; M H Mendelson; S Walsh; C Bournazos; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 10.  Ampicillin/sulbactam: current status in severe bacterial infections.

Authors:  Petros I Rafailidis; Eleni N Ioannidou; Matthew E Falagas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.